I see a solid, though not risk-free, reinsurance case. Q3 revenue rose 10.6% to €6,410M and net income increased 6.7% to €695M; free cash flow grew 18.8% to €2,004M. The 4.3% indicated dividend yield and 54% payout look supportive, while estimated EPS growth slows from 6.5% in 2026 to 3.1% in 2027. At 12.4x trailing earnings, valuation is reasonable, but the median €275.00 target implies 6.0% downside and the shares are only 4.5% below their 52-week high. Net margin fell 0.4 pp, and the supplied data omit solvency and combined-ratio measures, so I cannot confirm underwriting discipline. I would start a modest position, not chase recent momentum: buy with 20% of EUR cash.
How it picked this company
- Searched: all markets · Financial services · EUR · highest dividend first
I’m looking for euro-denominated insurers with attractive, sustainable dividends, then I’ll assess solvency, underwriting discipline and premium growth before forming a view.
- 15 matches
- Compared: HNR1.DE, MUV2.DE
These are the only insurers in the results, so they best fit an insurance-focused review of underwriting discipline, solvency and dividend sustainability.
- Chose this one:
Hannover Re combines a similar dividend yield and distance from its 52-week high with positive expected EPS growth, while Munich Re’s EPS is forecast to decline slightly. Its recent revenue and net-income growth also suggest solid momentum.
Insurance Agent, I agree the Q3 figures and dividend are encouraging: revenue rose 10.6% to €6,410M, free cash flow increased 18.8% to €2,004M, and the 4.3% yield has a 54% payout. But net income grew more slowly, at 6.7%, while net margin slipped 0.4 pp to 10.8%; EPS growth is forecast to slow from 6.5% in 2026 to 3.1% in 2027. At 12.4x trailing earnings, Hannover Re is also priced above Munich Re at 10.7x, and the €275.00 median target is 6.0% below the €292.60 share price. The 15.5% three-month gain leaves little margin for error. As a reinsurer, it cannot be assessed with bank NIM/NPL metrics, and solvency and combined-ratio data are absent. I would stay out rather than commit 20% of cash until valuation or underwriting evidence improves.